These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34515413)

  • 1. The rate of secondary genomic findings in the Saudi population.
    Aloraini T; Alsubaie L; Alasker S; Al Muitiri A; Alswaid A; Eyiad W; Al Mutairi F; Ababneh F; Alfadhel M; Alfares A
    Am J Med Genet A; 2022 Jan; 188(1):83-88. PubMed ID: 34515413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
    Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
    Chetruengchai W; Shotelersuk V
    J Hum Genet; 2022 Mar; 67(3):137-142. PubMed ID: 34621001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-exome sequencing of a Saudi epilepsy cohort reveals association signals in known and potentially novel loci.
    Al Anazi AH; Ammar AS; Al-Hajj M; Cyrus C; Aljaafari D; Khoda I; Abdelfatah AK; Alsulaiman AA; Alanazi F; Alanazi R; Gandla D; Lad H; Barayan S; Keating BJ; Al-Ali AK
    Hum Genomics; 2022 Dec; 16(1):71. PubMed ID: 36539902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of pathogenic variants in clinically actionable genes in a founder population.
    Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
    Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections.
    Ponińska JK; Bilińska ZT; Truszkowska G; Michalak E; Podgórska A; Stępień-Wojno M; Chmielewski P; Lutyńska A; Płoski R
    J Transl Med; 2022 Jan; 20(1):42. PubMed ID: 35078481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
    Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
    Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary findings in 421 whole exome-sequenced Chinese children.
    Chen W; Li W; Ma Y; Zhang Y; Han B; Liu X; Zhao K; Zhang M; Mi J; Fu Y; Zhou Z
    Hum Genomics; 2018 Sep; 12(1):42. PubMed ID: 30217213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
    Genet Med; 2022 Jul; 24(7):1407-1414. PubMed ID: 35802134
    [No Abstract]   [Full Text] [Related]  

  • 10. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Chung WK; Gordon AS; Herman GE; Klein TE; Stewart DR; Amendola LM; Adelman K; Bale SJ; Gollob MH; Harrison SM; Hershberger RE; McKelvey K; Richards CS; Vlangos CN; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1381-1390. PubMed ID: 34012068
    [No Abstract]   [Full Text] [Related]  

  • 11. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes.
    Jang MA; Lee SH; Kim N; Ki CS
    Genet Med; 2015 Dec; 17(12):1007-11. PubMed ID: 25856671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.
    Amendola LM; Jarvik GP; Leo MC; McLaughlin HM; Akkari Y; Amaral MD; Berg JS; Biswas S; Bowling KM; Conlin LK; Cooper GM; Dorschner MO; Dulik MC; Ghazani AA; Ghosh R; Green RC; Hart R; Horton C; Johnston JJ; Lebo MS; Milosavljevic A; Ou J; Pak CM; Patel RY; Punj S; Richards CS; Salama J; Strande NT; Yang Y; Plon SE; Biesecker LG; Rehm HL
    Am J Hum Genet; 2016 Jun; 98(6):1067-1076. PubMed ID: 27181684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy number alterations involving 59 ACMG-recommended secondary findings genes.
    Yatsenko SA; Aarabi M; Hu J; Surti U; Ortiz D; Madan-Khetarpal S; Saller DN; Bellissimo D; Rajkovic A
    Clin Genet; 2020 Dec; 98(6):577-588. PubMed ID: 33009833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding ACMG variant classification guidelines into a general framework.
    Masson E; Zou WB; Génin E; Cooper DN; Le Gac G; Fichou Y; Pu N; Rebours V; Férec C; Liao Z; Chen JM
    Hum Genomics; 2022 Aug; 16(1):31. PubMed ID: 35974416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.
    Huang Y; Liu B; Shi J; Zhao S; Xu K; Sun L; Chen N; Tian W; Zhang J; Wu N
    J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The updates of the ACMG variant interpretation guidelines affect the pathogenicity determination of
    Wu KL; Li J; Wang HY; Wang QJ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 May; 59(5):455-463. PubMed ID: 38811176
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduced penetrance of pathogenic ACMG variants in a deeply phenotyped cohort study and evaluation of ClinVar classification over time.
    van Rooij J; Arp P; Broer L; Verlouw J; van Rooij F; Kraaij R; Uitterlinden A; Verkerk AJMH
    Genet Med; 2020 Nov; 22(11):1812-1820. PubMed ID: 32665702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informing variant assessment using structured evidence from prior classifications (PS1, PM5, and PVS1 sequence variant interpretation criteria).
    Bhat V; Adzhubei IA; Fife JD; Lebo M; Cassa CA
    Genet Med; 2023 Jan; 25(1):16-26. PubMed ID: 36305854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Evaluation of the Utility of Whole Exome Sequencing in Dilated Cardiomyopathy.
    Ramchand J; Wallis M; Macciocca I; Lynch E; Farouque O; Martyn M; Phelan D; Chong B; Lockwood S; Weintraub R; Thompson T; Trainer A; Zentner D; Vohra J; Chetrit M; Hare DL; James P
    J Am Heart Assoc; 2020 Jan; 9(2):e013346. PubMed ID: 31931689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-frequency actionable pathogenic exome variants in an average-risk cohort.
    Rego S; Dagan-Rosenfeld O; Zhou W; Sailani MR; Limcaoco P; Colbert E; Avina M; Wheeler J; Craig C; Salins D; Röst HL; Dunn J; McLaughlin T; Steinmetz LM; Bernstein JA; Snyder MP
    Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30487145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.